Literature DB >> 23744558

Inhibition of angiogenesis: a novel antitumor mechanism of the herbal compound arctigenin.

Yuan Gu1, Claudia Scheuer, Dilu Feng, Michael D Menger, Matthias W Laschke.   

Abstract

Arctigenin, a functional ingredient of several traditional Chinese herbs, has been reported to have potential antitumor activity. However, its mechanisms of action are still not well elucidated. Because the establishment and metastatic spread of tumors is crucially dependent on angiogenesis, here we investigated whether arctigenin inhibits tumor growth by disturbing blood vessel formation. For this purpose, human dermal microvascular endothelial cells were exposed to different arctigenin doses to study their viability, proliferation, protein expression, migration, and tube formation compared with vehicle-treated controls. In addition, arctigenin action on vascular sprouting was analyzed in an aortic ring assay. Furthermore, we studied direct arctigenin effects on CT26.WT colon carcinoma cells. Spheroids of these tumor cells were transplanted into the dorsal skinfold chamber of arctigenin-treated and vehicle-treated BALB/c mice for the in-vivo analysis of tumor vascularization and growth by intravital fluorescence microscopy, histology, and immunohistochemistry. We found that noncytotoxic doses of arctigenin dose dependently reduced the proliferation of human dermal microvascular endothelial cells without affecting their migratory and tube-forming capacity. Arctigenin treatment also resulted in a decreased cellular expression of phosphorylated serine/threonine protein kinase AKT, vascular endothelial growth factor receptor 2, and proliferating cell nuclear antigen and inhibited vascular sprouting from aortic rings. In addition, proliferation, but not secretion of vascular endothelial growth factor, was decreased in arctigenin-treated tumor cells. Finally, arctigenin suppressed the vascularization and growth of engrafting CT26.WT tumors in the dorsal skinfold chamber model. Taken together, these results show for the first time an antiangiogenic action of arctigenin, which may contribute considerably toward its antitumor activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23744558     DOI: 10.1097/CAD.0b013e328362fb84

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  10 in total

1.  Portal branch ligation does not counteract the inhibiting effect of temsirolimus on extrahepatic colorectal metastatic growth.

Authors:  Sebastian Senger; Jens Sperling; Barbara Oberkircher; Martin K Schilling; Otto Kollmar; Michael D Menger; Christian Ziemann
Journal:  Clin Exp Metastasis       Date:  2017-06-19       Impact factor: 5.150

2.  Elucidation of arctigenin pharmacokinetics after intravenous and oral administrations in rats: integration of in vitro and in vivo findings via semi-mechanistic pharmacokinetic modeling.

Authors:  Qiong Gao; Yufeng Zhang; Siukwan Wo; Zhong Zuo
Journal:  AAPS J       Date:  2014-10-02       Impact factor: 4.009

3.  Intravital assessment of angioarchitecture in rat hepatocellular nodules using in vivo fluorescent microscopy.

Authors:  Yi Liu; Tao Lu; Congcong Wang; Hui Li; Ke Xu; Peiling Li
Journal:  Quant Imaging Med Surg       Date:  2019-06

4.  Linalool inhibits the angiogenic activity of endothelial cells by downregulating intracellular ATP levels and activating TRPM8.

Authors:  Vivien Becker; Xin Hui; Lisa Nalbach; Emmanuel Ampofo; Peter Lipp; Michael D Menger; Matthias W Laschke; Yuan Gu
Journal:  Angiogenesis       Date:  2021-03-02       Impact factor: 10.658

5.  Geraniol Suppresses Angiogenesis by Downregulating Vascular Endothelial Growth Factor (VEGF)/VEGFR-2 Signaling.

Authors:  Christine Wittig; Claudia Scheuer; Julia Parakenings; Michael D Menger; Matthias W Laschke
Journal:  PLoS One       Date:  2015-07-08       Impact factor: 3.240

6.  Inhibition of Hyaluronic Acid Synthesis Suppresses Angiogenesis in Developing Endometriotic Lesions.

Authors:  Carla N Olivares; Laura D Alaniz; Michael D Menger; Rosa I Barañao; Matthias W Laschke; Gabriela F Meresman
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

7.  Brassinin Promotes the Degradation of Tie2 and FGFR1 in Endothelial Cells and Inhibits Triple-Negative Breast Cancer Angiogenesis.

Authors:  Yuan Gu; Vivien Becker; Moqin Qiu; Tianci Tang; Emmanuel Ampofo; Michael D Menger; Matthias W Laschke
Journal:  Cancers (Basel)       Date:  2022-07-21       Impact factor: 6.575

8.  Arctigenin: pharmacology, total synthesis, and progress in structure modification.

Authors:  Dan Wu; Lili Jin; Xing Huang; Hao Deng; Qing-Kun Shen; Zhe-Shan Quan; Changhao Zhang; Hong-Yan Guo
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 9.  Replacement in angiogenesis research: Studying mechanisms of blood vessel development by animal-free in vitro, in vivo and in silico approaches.

Authors:  Matthias W Laschke; Yuan Gu; Michael D Menger
Journal:  Front Physiol       Date:  2022-08-17       Impact factor: 4.755

10.  Tubeimoside-1 suppresses tumor angiogenesis by stimulation of proteasomal VEGFR2 and Tie2 degradation in a non-small cell lung cancer xenograft model.

Authors:  Yuan Gu; Christina Körbel; Claudia Scheuer; Anca Nenicu; Michael D Menger; Matthias W Laschke
Journal:  Oncotarget       Date:  2016-02-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.